✦ LIBER ✦

Idarubicin plus attenuated high-dose cytosine arabinoside in the treatment of relapsed and refractory acute leukemia

✍ Scribed by L. Cavanna; M. Di Stasi; F. Fornari; G. Civardi; G. Sbolli; M. Moretto; L. Buscarini

Book ID: 114791332
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 195 KB
Volume: 45
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.1990.tb00450.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

High dose cytosine arabinoside (HDARAC)

High dose cytosine arabinoside (HDARAC) in refractory acute leukemia

✍ Seth A. Rudnick; Edwin C. Cadman; Robert L. Capizzi; Roland T. Skeel; Joseph R. 📂 Article 📅 1979 🏛 John Wiley and Sons 🌐 English ⚖ 415 KB 👁 2 views

Thirteen leukemic patients with disease refractory to conventional chemotherapy were treated with 1.0 to 7.5 g/m2 of Cytosine Arabinoside (Ara-C) over 29 drug cycles. Drug infusions were spaced at 12-hour intervals; a maximum of four doses was administered over 36 hours. After single dose tolerance

Treatment of relapsed and refractory acu

Treatment of relapsed and refractory acute leukaemia with high-dose cytosine arabinoside and etoposide

✍ Martin Gore; Ray Powles; Anil Lakhani; Sarah Milan; Jennifer Maitland; Glen Goss 📂 Article 📅 1989 🏛 Springer 🌐 English ⚖ 425 KB

A total of 65 patients under the age of 55 with acute leukaemia received high-dose cytosine arabinoside (Ara-C) in combination with high-dose etoposide without an anthracycline. Complete remission rates for patients with relapsed or refractory acute myelogenous leukaemia (AML) were 15/25 (60%) and 1

Idarubicin and standard-dose cytosine ar

Idarubicin and standard-dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia

✍ Merat Karbasian-Esfahani; Peter H. Wiernik; Yelena Novik; Elisabeth Paietta; Jan 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 79 KB 👁 1 views

## Abstract ## BACKGROUND Drug resistance and early disease recurrence were major contributing factors in the limited survival of patients with acute lymphocytic leukemia (ALL). New chemotherapeutic agents and drug combinations were employed in refractory patients to overcome drug resistance. ##

Sequential high-dose cytosine arabinosid

Sequential high-dose cytosine arabinoside and asparaginase in refractory acute leukemia

✍ Capizzi, Robert L. ;Cheng, Yung-Chi 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 551 KB

The development of resistance to Ara-C by leukemia cells may be a multifactorial process. These include diminished rates of anabolism or increased rate of catabolism to Ara-C, competition for incorporation into DNA by higher pool size of the competing normal metabolite, dCTP and perhaps other mechan

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia

✍ Ronald S. Walters; Hagop M. Kantarjian; Michael J. Keating; William K. Plunkett; 📂 Article 📅 1988 🏛 John Wiley and Sons 🌐 English ⚖ 547 KB

Forty-four patients with a diagnosis of refractory or relapsed acute myelogenous leukemia received salvage chemotherapy with high-dose cytosine arabinosine 3 g/m2 intravenously over 2 hours every 12 hours for six doses and mitoxantrone 5 mg/m2 intravenously daily for 5 days. Overall 16 patients (36%

Mitoxantrone and high-dose cytosine arab

Mitoxantrone and high-dose cytosine arabinoside for the treatment of refractory acute lymphocytic leukemia

✍ Hagop M. Kantarjian; Ronald L. Walters; Michael J. Keating; Elihu H. Estey; SUSA 📂 Article 📅 1990 🏛 John Wiley and Sons 🌐 English ⚖ 447 KB 👁 2 views

Twenty-five adult patients with refractory acute lymphocytic leukemia received salvage therapy with mitoxantrone 5 mg/m2 intravenously over 1 hour daily for 5 days and cytosine arabinoside 3 g/m2 intravenously over 2 hours every 12 hours for six doses. Overall, nine patients (36%) achieved complete